MAPK inhibition by 1α,25(OH)2–Vitamin D3 in breast cancer cells.

• DOI: 10.1016/j.jsbmb.2004.03.033
• Publication Date: 2004-05-08T07:37:11Z
• Authors: Ana M Rossi; Daniela A Capiati; Gabriela Picotto; Silvia Benassati; Ricardo L Boland
• Keywords: 0301 basic medicine; Blotting, Western; Proto-Oncogene Proteins pp60(c-src); Precipitin Tests; 3. Good health; 03 medical and health sciences; Calcitriol; Cell Line, Tumor; Humans; Receptors, Calcitriol; Amino Acid Sequence; Enzyme Inhibitors; Mitogen-Activated Protein Kinases

1alpha,25-Dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)], the hormonally active form of Vitamin D(3), has been shown to be a potent negative growth regulator of breast cancer cells both in vitro and in vivo. 1alpha,25(OH)(2)D(3) acts through two different mechanisms. In addition to regulating gene transcription via its specific intracellular receptor (Vitamin D receptor, VDR), 1alpha,25(OH)(2)D(3) induces, rapid, non-transcriptional responses involving activation of transmembrane signal transduction pathways. The mechanisms that mediate the antiproliferative effects of 1alpha,25(OH)(2)D(3) in breast cancer cells are not fully understood. Particularly, there is no information about the early non-genomic signal transduction effectors modulated by the hormone. The present study shows that 1alpha,25(OH)(2)D(3) rapidly inhibits serum induced activation of ERK-1 and ERK-2 MAP kinases. The non-receptor tyrosine kinase Src is involved in the pathway leading to activation of ERK 1/2 by serum. Furthermore, 1alpha,25(OH)(2)D(3) increases the tyrosine-phosphorylated state of Src as well as it inhibits its kinase activity and induces the association of the VDR with Src. These data suggest that 1alpha,25(OH)(2)D(3) inhibits MAPK by inactivating Src tyrosine kinase through a so far unknown mechanism that seems to be mediated by the VDR.